For most people, an infection with SARS-CoV-2 is self-limiting, but for hospitalised patients, mortality is high (10-20%) and for ventilated patients even higher (40-50%). The pathophysiology of COVID-19 is characterised by 2 components: a viral response in the first week to 10 days, and an increasing inflammatory response, where the immune system is initially combating the virus but can also drive lung damage and need for ventilation.
Current treatment falls into 3 categories: repurposed anti-virals, immunomodulatory drugs, and some drugs targeted specifically at SARS-CoV-2. In addition, there are some treatments targeted at complications, such as antithrombotics. Currently, hundreds of candidate drugs exist but very little reliable data is available (only uncontrolled case series and inconclusive randomised trials). According to Prof. Landray, it is worth remembering that it is unlikely to have a single “big win,” but that moderate benefits will be important.
RECOVERY trial
The controlled, open-label RECOVERY trial evaluated hospitalised patients with SARS-CoV-2 in 176 hospitals in the United Kingdom and Northern Ireland [2]. The most important outcome was 28-day mortality, but it also evaluated use of ventilation and duration of hospitalisation. Patients were randomised between a range of suitable and available treatments:
- repurposed antivirals, i.e. hydroxychloroquine and lopinavir-ritonavir;
- immunomodulatory drugs, i.e. dexamethasone, azithromycin, and tocilizumab; and
- targeted anti-SARS-CoV-2, i.e. convalescent plasma.
Both hydroxychloroquine and lopinavir-ritonavir had no effect on all-cause mortality among these hospitalised patients. In contrast, dexamethasone reduced mortality with about a third in patients requiring oxygen or ventilation.
Remdesivir and tocilizumab
In a similar patient population, a double-blind, randomised, placebo-controlled trial found that remdesivir reduced time to recovery with approximately 4 days (11 vs 15 days; RR 1.32; P<0.001) [3]. However, no impact on mortality was found (RR 0.70).
There is one reported trial evaluating the anti-IL-6 monoclonal antibody tocilizumab. This relatively small study showed no impact on either clinical status (OR 1.19; P=0.36) or mortality (19.7 vs 19.4%; P=0.94) at day 28, but did observe a shorter hospitalisation duration (20 vs 28 days; P=0.04). Additional studies are ongoing, including the evaluation of >800 patients in the RECOVERY study.
Figure: Incidence of in-hospital events in COVID-19 patients [1]

- Landray M. Randomized trials of COVID-19 treatments. COVID and Cardiovascular Disease session, ESC Congress 2020, 30 Aug.
- The RECOVERY Collaborative Group. N Engl J Med 2020; 17 July. DOI: 10.1056/NEJMoa2021436.
- Beigel JH, et al. N Engl J Med 2020; 22 May. DOI: 10.1056/NEJMoa2007764.
Posted on
Previous Article
« Bezafibrate improves itch in patients with cholestatic diseases Next Article
The Yale COVID-19 Cardiovascular Registry »
« Bezafibrate improves itch in patients with cholestatic diseases Next Article
The Yale COVID-19 Cardiovascular Registry »
Table of Contents: ESC 2020
Featured articles
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Late-Breaking Science
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
Related Articles
November 5, 2020
POPular TAVI: Aspirin-only antiplatelet strategy?
November 5, 2020
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com